However, a pilot study of progressive platinum-resistant OC demonstrated minimal anti-tumour effects with ACT following lymphodepletion and IL-2 therapy, with four out of six patients showing stable disease for only three months and two out of six patients for five months. The gene discussed is IL2; the disease is neoplasm.